Larotrectinib in adult patients with TRK fusion cancer: an expanded data set
The highly selective TRK inhibitor Larotrectinib ( Vitrakvi ) is approved for the treatment of adult and pediatric cancers that harbor NTRK gene fusions; it achieves a 79% overall response rate ( ORR ) in this population ( Hong et al., Lancet Oncol 2020 ).
The activity of Larotrectinib in adults alone was further characterized in this update with a larger series of patients and more mature durability data.
Adults ( aged 18 years or older ) with TRK fusion cancer treated in three Larotrectinib clinical trials ( NCT02122913, NCT02576431, and NCT02637687 ) were analyzed.
Larotrectinib was administered 100 mg BID until disease progression, withdrawal, or unacceptable toxicity.
ORR was investigator-assessed ( RECIST v1.1 ).
Compared to previously presented data on 74 patients, this expanded data set has included an additional 42 patients ( data cutoff: July 15, 2019 ).
116 adults ( median age: 56 years, range 19–84 years; 53% female ) with TRK fusion cancer were treated.
Tumor types included thyroid cancer ( 22% ), salivary gland cancer ( 19% ), soft tissue sarcoma ( 16% ), lung cancer ( 12% ), colon cancer ( 7% ), melanoma ( 5% ), breast cancer ( 5% ), GIST ( 3% ), and 9 other types ( 2% or less each ).
NTRK fusions involved NTRK1 ( 43% ), NTRK2 ( 3% ), and NTRK3 ( 54% ).
78% of patients had received prior systemic therapy ( with 68% of those receiving 2 or more prior therapies ).
The ORR was 71% ( 95% CI 62–79 ): 10% complete response [ CR ], 60% partial response [ PR ] ( 2% pending confirmation ), 16% stable disease, 9% progressive disease, 3% not determined.
In patients with brain metastases, the ORR was 71% ( 95% CI 42–92; 10 of 14 patients, all partial responses ).
Median duration of response for the overall data set ( n = 116 ) was 35.2 months ( 95% CI 21.6–not estimable [ NE ] ).
Median progression-free survival was 25.8 months ( 95% CI 15.2–NE ). Median overall survival was not reached ( range 0.5+ to 51.6+ months ) at a median follow-up of 15.8 months.
Duration of treatment ranged from 0.10 to 51.6+ months.
12% of patients had dose reductions. One patient ( 1% ) discontinued due to a Larotrectinib-related adverse event.
Adverse effects were mostly grade 1–2; no new unexpected adverse effects were reported.
In conclusion, in an expanded data set of adults with TRK fusion cancer, Larotrectinib demonstrated robust and durable tumor-agnostic efficacy and favorable safety, supporting NTRK gene fusion testing in patients with solid tumors of any type. ( Xagena )
Source: American Society of Clinical Oncology ( ASCO ) Virtual Meeting, 2020
Resected stage III melanoma with BRAF mutations: 5-year follow-up of adjuvant Dabrafenib plus Trametinib - Findings from the COMBI-AD study
Data from the five-year analysis featuring extended follow-up from the phase III COMBI-AD study have confirmed that 12 months of...
Efficacy and safety of Pembrolizumab plus chemotherapy to Pembrolizumab monotherapy: a consecutive analysis of NSCLC patients with high PD-L1 expression
There has been an only indirect comparison between Pembrolizumab ( Keytruda ) and Pembrolizumab plus chemotherapy in patients with non-small...
Primary Ipilimumab / Nivolumab immunotherapy followed by adjuvant Nivolumab in locally advanced or oligometastatic melanoma: preliminary results
The aim of neo-adjuvant therapy in locally advanced or oligometastatic melanoma is to facilitate radical resection, improve outcomes and undertake...
ALEX study: updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer
The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib (...
In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for...
The mRNA-1273 vaccine for SARS-CoV-2 is tolerable and immunogenic in older adults. Data on prolonged immunogenicity and effectiveness in preventing severe...
Ayvakyt for the treatment of adults with unresectable or metastatic PDGFRA D842V mutant gastrointestinal stromal tumors, approved by European Commission
The European Commission ( EC ) has granted conditional marketing authorization to Ayvakyt ( Avapritinib ) as a monotherapy for...
The U.S. Food and Drug Administration ( FDA ) has approved Gallium 68 PSMA-11 ( Ga 68 PSMA-11 ), the...
FDA has approved Ayvakit, the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
The FDA ( U.S. Food and Drug Administration ) has approved Ayvakit ( Avapritinib ) for the treatment of adults...
European Commission has approved expanded use of Erleada for treatment of patients with metastatic hormone-sensitive prostate cancer
The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...